Evidence map›Paper›PMID 39719461›Full record

ArticleAdvances in therapy2025

Clinical Features and Current Pharmacotherapy of OAB in Practice: Ideal and Reality.

Kazuna Tsubouchi, Hisatomi Arima, Taiki Emoto, Hiroshi Nakazawa, Takahiro Kitano, Masashi Mikami, Chikao Aoyagi, Hiroshi Matsuzaki, Kosuke Tominaga, Naotaka Gunge and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kazuna TsubouchiDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Hisatomi ArimaDepartment of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Taiki EmotoDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Hiroshi NakazawaPfizer Japan Inc., Tokyo, Japan.
Takahiro KitanoPfizer Japan Inc., Tokyo, Japan.
Masashi MikamiPfizer Japan Inc., Tokyo, Japan.
Chikao AoyagiDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Hiroshi MatsuzakiDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Kosuke TominagaDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Naotaka GungeDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Takeshi MiyazakiDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Yu OkabeDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Nobuyuki NakamuraDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Yuichiro FukuharaDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Masahiro TachibanaDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Chizuru NakagawaDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Fumihiro YamazakiDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Nobuhiro HagaDepartment of Urology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan. nhaga@fukuoka-u.ac.jp.ORCID 0000-0003-3618-5214

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe present study aimed to investigate the prescribing patterns of anticholinergics (anti-AChR) or β3-adrenergic agonists (β

methodsThis cohort study was conducted using the JMDC claims database between May 2015 and April 2023. Patient characteristics, prescription and treatment patterns of anti-AChR and β

resultsOverall, 70,936 patients were analyzed [mean age, 53.6 (standard deviation: 12.3) years]. Among women (48.5%; 34,439), 21.4% initially received anti-AChR and 27.2% received β

conclusionThis large-scale database study revealed that treatment for OAB is often initiated with β

Indexed as

Adrenergic beta-3 Receptor AgonistsCholinergic AntagonistsPractice Patterns, Physicians'Urinary Bladder, OveractiveAdultAgedCohort StudiesDatabases, FactualFemaleHumansMaleMiddle AgedAdrenergic beta-3 Receptor AgonistsCholinergic AntagonistsAdministrative databaseAdrenergic β3 agonistAnticholinergicClaims databaseJapanOveractive bladderPrescriptionRetrospective studyUrinary tract infections

Identifiers

PMID39719461
PMCPMC11787252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.